Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroglycerin for Prevention of Contrast-Induced Nephropathy
NCT01999517Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2013
- Primary completion
- Jun 2018
- Countries
- 1
- Sponsor
- Mount Sinai Medical Center
- Modality
- Small Molecules
- Drugs
- nitroglycerin
- Conditions
- contrast-induced nephropathy (CIN)
01
Overview
Phase 4, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing Intravenous Nitroglycerin with Placebo (2 arms). Primary endpoint: Change in Glomerular Filtration Rate. Started Jun 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Intravenous Nitroglycerin
IV Nitroglycerin with IV Fluids
Placebo
IV Fluids
03
Who it enrols
Patients scheduled for percutaneous coronary angiography with a Mehran score >= 6. Excludes patients on renal replacement therapy, those exposed to nitrates within 48 hours or contrast media within 4 days, hypotensive patients (<90/60 mmHg), and those with planned revascularization in the next 24-48 hours.
04
Endpoints
Primary
Change in Glomerular Filtration Rate
Secondary
Incidence of Contrast Induced Nephropathy
Beyond the preview
Go deeper on NCT01999517.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999517.